dc.contributor.author
Sperber, Pia S.
dc.contributor.author
Brandt, Alexander U.
dc.contributor.author
Zimmermann, Hanna G.
dc.contributor.author
Bahr, Lina S.
dc.contributor.author
Chien, Claudia
dc.contributor.author
Rekers, Sophia
dc.contributor.author
Mähler, Anja
dc.contributor.author
Böttcher, Chotima
dc.contributor.author
Asseyer, Susanna
dc.contributor.author
Duchow, Ankelien Solveig
dc.contributor.author
Bellmann-Strobl, Judith
dc.contributor.author
Ruprecht, Klemens
dc.contributor.author
Paul, Friedemann
dc.contributor.author
Schmitz-Hübsch, Tanja
dc.date.accessioned
2023-11-30T16:29:47Z
dc.date.available
2023-11-30T16:29:47Z
dc.identifier.uri
https://refubium.fu-berlin.de/handle/fub188/41672
dc.identifier.uri
http://dx.doi.org/10.17169/refubium-41392
dc.description.abstract
Background: Large-scale disease overarching longitudinal data are rare in the field of neuroimmunology. However, such data could aid early disease stratification, understanding disease etiology and ultimately improve treatment decisions. The Berlin Registry of Neuroimmunological Entities (BERLimmun) is a longitudinal prospective observational study, which aims to identify diagnostic, disease activity and prognostic markers and to elucidate the underlying pathobiology of neuroimmunological diseases.
Methods: BERLimmun is a single-center prospective observational study of planned 650 patients with neuroimmunological disease entity (e.g. but not confined to: multiple sclerosis, isolated syndromes, neuromyelitis optica spectrum disorders) and 85 healthy participants with 15 years of follow-up. The protocol comprises annual in-person visits with multimodal standardized assessments of medical history, rater-based disability staging, patient-report of lifestyle, diet, general health and disease specific symptoms, tests of motor, cognitive and visual functions, structural imaging of the neuroaxis and retina and extensive sampling of biological specimen.
Discussion: The BERLimmun database allows to investigate multiple key aspects of neuroimmunological diseases, such as immunological differences between diagnoses or compared to healthy participants, interrelations between findings of functional impairment and structural change, trajectories of change for different biomarkers over time and, importantly, to study determinants of the long-term disease course. BERLimmun opens an opportunity to a better understanding and distinction of neuroimmunological diseases.
en
dc.rights.uri
https://creativecommons.org/licenses/by/4.0/
dc.subject
Multiple sclerosis (MS)
en
dc.subject
Clinically isolated syndrome (CIS)
en
dc.subject
Neuromyelitis optica spectrum disorder
en
dc.subject
Myelin-oligodendrocytic-glycoprotein
en
dc.subject
associated disease (MOGAD)
en
dc.subject
Optic neuritis
en
dc.subject
Prospective observational study
en
dc.subject.ddc
600 Technik, Medizin, angewandte Wissenschaften::610 Medizin und Gesundheit::610 Medizin und Gesundheit
dc.title
Berlin Registry of Neuroimmunological entities (BERLimmun): protocol of a prospective observational study
dc.type
Wissenschaftlicher Artikel
dcterms.bibliographicCitation.articlenumber
479
dcterms.bibliographicCitation.doi
10.1186/s12883-022-02986-7
dcterms.bibliographicCitation.journaltitle
BMC Neurology
dcterms.bibliographicCitation.number
1
dcterms.bibliographicCitation.originalpublishername
Springer Nature
dcterms.bibliographicCitation.volume
22
refubium.affiliation
Charité - Universitätsmedizin Berlin
refubium.funding
Springer Nature DEAL
refubium.resourceType.isindependentpub
no
dcterms.accessRights.openaire
open access
dcterms.bibliographicCitation.pmid
36517734
dcterms.isPartOf.eissn
1471-2377